- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001382
A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate
Study Overview
Detailed Description
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Cancer Institute (NCI)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma of the prostate as follows: Unresectable and/or incurable tumor AND Tumor progression after at least 1 prior hormonal manipulation (i.e., LHRH agonist/flutamide or orchiectomy). LHRH agonist may by continued concurrently with protocol therapy.
New bone or soft tissue lesions OR Serum PSA that has risen on 3 successive evaluations at least 1 week apart during and/or after hormonal therapy. If PSA is below 4 ng/mL, measurable disease with positive immunohistochemical stain for PSA is required.
No history of allergy to eggs.
No history of or active CNS metastases.
Symptomatic spinal or other bony metastasis should be irradiated prior to entry.
Bi-dimensionally measurable disease not required.
PRIOR/CONCURRENT THERAPY:
Biologic Therapy:
No concurrent Biologic Therapy.
Must fully recover from prior Biologic Therapy.
Chemotherapy:
At least 4 weeks since prior chemotherapy and fully recovered.
No more than 1 prior chemotherapy regimen.
No concurrent chemotherapy.
Endocrine Therapy:
See Disease Characteristics.
At least 4 weeks since prior hormonal therapy and fully recovered.
No concurrent steroids.
Radiotherapy:
At least 4 weeks since prior radiation therapy and fully recovered.
No prior radiotherapy to more than 50% of nodal groups.
No concurrent radiotherapy.
Surgery:
At least 4 weeks since prior surgery, with surgical scar healed.
No prior splenectomy.
PATIENT CHARACTERISTICS:
Age: Over 18.
Performance status: Zubrod (ECOG) 0-2.
Hematopoietic:
Absolute granulocyte count greater than 2,000/mm(3);
Platelet count greater than 100,000/mm(3);
Hemoglobin greater than 8.0 g/dL.
Hepatic:
Bilirubin less than 1.6 mg/dL;
AST and ALT less than 4 times normal.
Renal: Creatinine less than 1.6 mg/dL.
Immunologic:
Prior vaccinia (for smallpox immunization) required, with proof of vaccination as follows: Detectable anti-vaccinia antibodies, Physician certification of prior vaccination, Patient recollection or appropriate vaccination-site scar sufficient in patients over age 25, Delayed-type hypersensitivity skin testing (to mumps, Candida, and Trichophyton antigens) normal Quantitative immunoglobulins normal.
No evidence of immunocompromise, i.e.:
No HIV antibody;
No eczema or atopic dermatitis;
No autoimmune neutropenia, thrombocytopenia, or hemolytic anemia;
No systemic lupus erythematosus, Sjogren syndrome, or scleroderma;
No myasthenia gravis;
No Goodpasture syndrome;
No Addison's disease, Hashimoto's thyroiditis, or active Graves' disease;
No other autoimmune disease or diagnosis of altered immune function.
OTHER:
No active case or history of extensive psoriasis, severe acneiform rash, impetigo, varicella zoster, burns, or other traumatic or pruritic skin condition.
No active infection requiring antibiotics (including chronic suppressive therapy). At least 3 days since antibiotic therapy.
No history of seizures, encephalitis, or multiple sclerosis.
No other serious intercurrent illness.
Able to avoid close contact with the following individuals for at least 2 weeks after vaccination (i.e., no such individuals as household members and no care-giving responsibilities for such individuals): Children under age 3, Pregnant women, Individuals with eczema or skin conditions defined above, Leukemia or lymphoma patients, HIV-positive individuals, Patients receiving immunosuppressive therapy, Any other immunosuppressed individuals.
No prior malignancy unless curatively treated and patient has been in remission for at least 2 years (excluding squamous cell or basal cell carcinoma of the skin or carcinoma in situ of the cervix).
Able and willing to travel to the NIH, NCI-NMOB, or the Lombardi Cancer Center at Georgetown University for treatment and follow-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 940118
- 94-C-0118
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
Clinical Trials on PROSTVAC
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Active, not recruiting
-
National Cancer Institute (NCI)CompletedProstate CancerUnited States
-
National Cancer Institute (NCI)CompletedProstatic Neoplasms | Prostate Cancer | Neoplasms, ProstateUnited States
-
National Cancer Institute (NCI)Active, not recruitingProstate Cancer | Prostate Neoplasms | Neoplasms, ProstaticUnited States
-
Medical University of South CarolinaBavarian NordicCompletedProstatic NeoplasmsUnited States
-
Bavarian NordicCompletedProstate Cancer MetastaticUnited States, Spain, Germany, Netherlands, Belgium, United Kingdom, Australia, Denmark, France, Canada, Israel, Russian Federation, Puerto Rico, Estonia, Poland, Iceland
-
University of UtahGenentech, Inc.; Bavarian NordicWithdrawnProstate AdenocarcinomaUnited States
-
Bavarian NordicNational Cancer Institute (NCI); Therion Biologics CorporationCompletedProstate CancerUnited States
-
National Cancer Institute (NCI)CompletedProstate CancerUnited States